Ventyx Biosciences, Inc. (VTYX)
Automate Your Wheel Strategy on VTYX
With Tiblio's Option Bot, you can configure your own wheel strategy including VTYX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTYX
- Rev/Share 0.0203
- Book/Share 2.6838
- PB 5.1476
- Debt/Equity 0.0524
- CurrentRatio 17.8607
- ROIC -0.5796
- MktCap 985819584.0
- FreeCF/Share -1.2323
- PFCF -11.2196
- PE -9.2402
- Debt/Assets 0.0474
- DivYield 0
- ROE -0.4811
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | VTYX | H.C. Wainwright | Neutral | Buy | -- | $18 | Nov. 5, 2025 |
News
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)
Published: January 08, 2026 by: Newsfile Corp
Sentiment: Neutral
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (NYSE: LLY) for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The investigation concerns whether the Ventyx Board breached its fiduciary duties to shareholders …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX
Published: January 08, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports
Published: January 06, 2026 by: Reuters
Sentiment: Positive
Eli Lilly is in advanced talks to buy Ventyx Biosciences for over $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Read More
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter
Published: January 06, 2026 by: WSJ
Sentiment: Positive
The more-than-$1 billion deal could come imminently.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX
Published: January 01, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX
Published: December 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX
Published: December 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
Read More
Ventyx Biosciences, Inc. (VTYX) Is Up 20.81% in One Week: What You Should Know
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Ventyx Biosciences, Inc. (VTYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference Location: Boston, MADate: Friday, September 5, 2025Time: 11:00-11:35 AM EDT Morgan Stanley 23 rd Annual Global Healthcare Conference Location: New York, NYDate: Monday, September 8, 2025 H.C. Wainwright 27th Annual Global Investment Conference Location: New York, NYDate: Monday, September 8, 2025 A webcast of the Wells Fargo presentation will …
Read More
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Ventyx Biosciences (VTYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's …
Read More
About Ventyx Biosciences, Inc. (VTYX)
- IPO Date 2021-10-21
- Website https://www.ventyxbio.com
- Industry Biotechnology
- CEO Raju S. Mohan
- Employees 81